Medicine and Dentistry
Hodgkin's Lymphoma
100%
Neoplasm
80%
Diffuse Large B-Cell Lymphoma
61%
Diseases
53%
Overall Survival
46%
Progression Free Survival
46%
Non-Hodgkin Lymphoma
39%
Doxorubicin
38%
Brentuximab Vedotin
34%
Reproducibility
32%
Student T Test
32%
Sensitivity and Specificity
32%
Rituximab
32%
Follicular Lymphoma
31%
Radiation Therapy
31%
Classical Hodgkin Lymphoma
28%
ABVD
26%
Vinblastine
22%
Adverse Event
21%
Prognostic Factor
19%
Mantle Cell Lymphoma
18%
Arm
17%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
17%
Ibrutinib
15%
Vincristine
15%
Malignant Neoplasm
15%
Dacarbazine
14%
Cyclophosphamide
14%
Autologous Stem Cell Transplantation
14%
Positron Emission Tomography
14%
Lenalidomide
13%
Cancer Research
13%
Bleomycin
13%
Breast Cancer
12%
B Cell
11%
B-Cell Lymphoma
11%
Peripheral T-Cell Lymphoma
10%
Prednisolone
10%
Etoposide
10%
T Cell
10%
Event Free Survival
10%
High Dose Chemotherapy
9%
Subgroup Analysis
9%
Loncastuximab Tesirine
9%
Disease Exacerbation
9%
Hazard Ratio
9%
MALT Lymphoma
9%
Interstitial Cell
8%
Tositumomab
8%
Clinical Feature
8%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
66%
Hodgkin Disease
58%
Diffuse Large B Cell Lymphoma
47%
Progression Free Survival
42%
Disease
41%
Rituximab
39%
Doxorubicin
37%
Overall Survival
35%
Brentuximab Vedotin
30%
Follicular Lymphoma
29%
Nonhodgkin Lymphoma
28%
Vincristine
20%
Malignant Neoplasm
20%
Classical Hodgkin Lymphoma
19%
Remission
18%
Cyclophosphamide
18%
Adverse Event
18%
Mantle Cell Lymphoma
16%
Etoposide
16%
Vinblastine
16%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
13%
Ibrutinib
13%
Loncastuximab Tesirine
13%
Event Free Survival
13%
Bleomycin
13%
Dacarbazine
12%
Tolerability
12%
Lenalidomide
11%
Small Cell Lung Cancer
11%
Ifosfamide
11%
Monotherapy
10%
Prednisolone
9%
Anthracycline
9%
Disease Exacerbation
9%
High Dose Chemotherapy
9%
Soft Tissue Sarcoma
8%
Ofatumumab
8%
Iodine-131
8%
Tositumomab
8%
Biological Marker
8%
Neutropenia
8%
Second Cancer
8%
B Cell Lymphoma
8%
Neoplasm
7%
Phase II Trials
7%
Comorbidity
7%
Cohort Study
7%
Tositumomab I 131
6%
Ibritumomab Tiuxetan
6%
Osteosarcoma
6%